-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to China's National Medical Security Administration, the negotiation of the 2022 national medical insurance drug catalogue officially ended on January 8, and the combination packaging of nematevir tablets / ritonavir tablets (hereinafter referred to as "Paxlovid") failed to be included in the medical insurance catalog through negotiation, but medical insurance can temporarily pay for the drug until March 31, and azvudine tablets and lung cleansing detoxification granules were included in the national medical insurance drug list
after this negotiation 。
It is known that this year, a total of 3 new crown treatment drugs, Azvudine tablets, Paxlovid and lung cleansing and detoxification granules, participated in the negotiations through the
procedures of self-declaration, formal review, and expert review.
Among them, the negotiation of azvudine tablets and lung cleansing and detoxification granules was successful, and Paxlovid was unsuccessful
due to the high quotation of the manufacturer Pfizer Investment Co.
, Ltd.
The person in charge of the Department of Medical Administration of the National Medical Security Administration said that although Paxlovid could not be included in the medical insurance catalogue through negotiation, according to the requirements of the "Notice on Optimizing the Medical Security Policy for the Treatment Cost of Patients with Novel Coronavirus Infection after the Implementation of "Class B and B Tube" jointly issued by the National Medical Insurance Administration and relevant departments, all therapeutic drugs in the "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)", including Paxlovid, Azvudine tablets, Monoravir capsules, cold and wet granules, etc.
, will be temporarily paid by medical insurance until March 31
, 2023.
During this period, insured patients with new coronavirus infection can enjoy medical insurance reimbursement policies for these drugs
.
The person in charge said that after Azvudine tablets and lung cleansing detoxification granules were included in the national medical insurance drug list after this negotiation, there are more than 600 kinds
of drugs in the national medical insurance drug list to treat fever, cough and other new crown symptoms.
At the same time, in order to meet the needs of the treatment of patients infected with new coronavirus infection in various places, local medical insurance departments have recently temporarily included a batch of new crown symptomatic treatment drugs into the payment scope
of local medical insurance in combination with the operation of local medical insurance funds.
In general, medical insurance reimburses a wide
range of drugs for the treatment of new coronavirus infection.
The person in charge also said that the Office of the National Health Insurance Administration recently issued the "Guidelines for the Formation of New Crown Treatment Drugs (Trial)", which adopts full-cycle and multi-level measures to guide enterprises to open, transparent and reasonable pricing
for newly marketed antiviral therapeutic drugs needed for the prevention and treatment of new coronavirus infection.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
